{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:55:24Z","timestamp":1787774124031,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) remains incurable although a subset of patients achieves survival \u226510\u00a0years. However, whether nutritional background predicted long-term survival (LTS), which defined as overall survival (OS) over 10\u00a0years, or not remains unclear. This retrospective study aimed to identify the clinical and nutritional factors associated with LTS in patients with MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed data from 163 patients with newly diagnosed MM aged &amp;lt;80\u00a0years between 2009 and 2014. Geriatric nutritional risk index (GNRI) was a nutritious biomarker and calculated by height, weight, and serum albumin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The perception of LTS was 20.9%. The cutoff of GNRI was defined as 91.715 using receiver operating characteristic curve to predict LTS. High GNRI was associated with low incidence of CRAB symptoms and international staging system III in patient characteristics. In the 4.6-year median follow-up period, 10-year OS rate in high GRNI group was higher than those in the low GNRI group (39.6% vs 27.9%; hazard ratio [HR], 0.667; P\u00a0=\u00a0.050). In the multivariate analysis, high GNRI and early progressive disease (PD) were identified as significant prognostic factors for OS (HR, 0.538; P\u00a0=\u00a0.049, and HR, 1.848; P\u00a0=\u00a0.040, respectively). We explored a new prognostic model using GNRI and early PD status; the 10-year OS rate in patients with high GNRI without early PD were 49.2%. High GNRI was independent predictors of LTS, and predicted long OS combining with early PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prognostic significance of host nutritional status played an important role for long survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag040","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:46:32Z","timestamp":1772023592000},"page":"849-857","source":"Crossref","is-referenced-by-count":2,"title":["Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Gunji","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Nagao","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Uryu","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Katsube","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hattori","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuji","family":"Katori","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hirano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]},{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University Kashiwa Hospital , Chiba 277-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of internal medicine, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026070605422839300_ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026070605422839300_ref2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"2026070605422839300_ref3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma -an IMWG research project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"key":"2026070605422839300_ref4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clml.2024.11.001","article-title":"Characteristics and treatment patterns of long-surviving patients with multiple myeloma: over 13 years of follow-up in the connect MM registry","volume":"25","author":"Terebelo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026070605422839300_ref5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1080\/10428194.2021.2012665","article-title":"Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances","volume":"63","author":"Bojalil-Alvarez","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026070605422839300_ref6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: relationship to inflammation and nutrition","volume":"17","author":"Don","year":"2004","journal-title":"Semin Dial"},{"key":"2026070605422839300_ref7","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070605422839300_ref8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","article-title":"Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients","volume":"82","author":"Bouillanne","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"2026070605422839300_ref9","doi-asserted-by":"crossref","first-page":"1274592","DOI":"10.3389\/fnut.2023.1274592","article-title":"Geriatric nutritional risk index as a predictor of prognosis in hematologic malignancies: a systematic review and meta-analysis","volume":"10","author":"Yu","year":"2023","journal-title":"Front Nutr"},{"key":"2026070605422839300_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutos.2025.12.003","article-title":"Geriatric nutritional risk index predicted survival time in multiple myeloma","volume":"65","author":"Suzuki","year":"2026","journal-title":"Clin Nutr Open Sci"},{"key":"2026070605422839300_ref11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026070605422839300_ref12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"2026070605422839300_ref13","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026070605422839300_ref14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026070605422839300_ref15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026070605422839300_ref16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/ajh.70012","article-title":"Determinants of 15-year progression-free survival in multiple myeloma; real-world data from a single institution","volume":"100","author":"Dimopoulos","year":"2025","journal-title":"Am J Hematol"},{"key":"2026070605422839300_ref17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/hon.2760","article-title":"The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine","volume":"38","author":"Nishiyama-Fujita","year":"2020","journal-title":"Hematol Oncol"},{"key":"2026070605422839300_ref18","doi-asserted-by":"publisher","first-page":"e0228738","DOI":"10.1371\/journal.pone.0228738","article-title":"Geriatric nutritional risk index predicts poor outcomes in patients with acute ischemic stroke - automated undernutrition screen tool","volume":"15","author":"Kang","year":"2020","journal-title":"PloS One"},{"key":"2026070605422839300_ref19","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40520-020-01656-3","article-title":"Prognostic value of geriatric nutritional risk index in elderly patients with heart failure: a meta-analysis","volume":"33","author":"Li","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"2026070605422839300_ref20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cncr.34545","article-title":"Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma","volume":"129","author":"Nandakumar","year":"2023","journal-title":"Cancer."},{"key":"2026070605422839300_ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.2003.04456.x","article-title":"A new staging system for multiple myeloma patients based on the southwest oncology group (SWOG) experience","volume":"122","author":"Jacobson","year":"2003","journal-title":"Br J Haematol"},{"key":"2026070605422839300_ref22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave","year":"2021","journal-title":"Br J Haematol"},{"key":"2026070605422839300_ref23","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/bloodadvances.2023009681","article-title":"Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy","volume":"7","author":"Charalampous","year":"2023","journal-title":"Blood Adv"},{"key":"2026070605422839300_ref24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026070605422839300_ref25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12185-025-03941-1","article-title":"Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients","volume":"121","author":"Suzuki","year":"2025","journal-title":"Int J Hematol"},{"key":"2026070605422839300_ref26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026070605422839300_ref27","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/blood.2025029987","article-title":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling","volume":"146","author":"Beer","year":"2025","journal-title":"Blood."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/849\/67368082\/hyag040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/849\/67368082\/hyag040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:42:33Z","timestamp":1783330953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/7\/849\/8524690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag040","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,16]]}}}